Linagliptin

Pharm Company: * AUROBINDO PHARMA LTD
Category: Diabetes

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".

Linagliptin Overview

Linagliptin (INN,[2] previously known as BI-1356, marketed under trade names Tradjenta (U.S.) and Trajenta (worldwide)) is a dipeptidyl peptidase-4 inhibitor developed by Boehringer Ingelheim for treatment of diabetes mellitus type 2. Once-daily linagliptin was approved by the U.S. Food and Drug Administration (FDA) on 2 May 2011 for treatment of type 2 diabetes.[3] It is being marketed by Boehringer Ingelheim and Lilly. Contents 1 Medical uses 2 Side effec...

Read more Linagliptin Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Linagliptin

Recent Linagliptin Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Other drugs which contain Linagliptin or a similar ingredient: (5 results)

• TRADJENTA Linagliptin4 discussions
• EMPAGLIFLOZIN + LINAGLIPTIN
• GLYXAMBI Empagliflozin + Linagliptin
• JENTADUETO XR Linagliptin + Metformin Hydrochloride
• LINAGLIPTIN + METFORMIN HYDROCHLORIDE

Related Linagliptin Topics: